HiTE™ Lunch & Learn at Penn CCI

​Struggling with low transduction efficiency, high vector costs, or complex workflows? Join us over lunch for a live introduction to HiTE™ (High-Efficiency Transduction Enhancer) — a first-in-class Transient Fusion-Promoting Peptide (TFP) technology that is redefining what's possible in lentiviral transduction.

What we'll cover:

How HiTE™ works
A bi-functional synthetic peptide that binds both lentiviral envelope proteins and target cell membranes, promoting virus-cell proximity and membrane fusion, then self-inactivates within hours to preserve cell health.

Head-to-head performance data at MOI 5, n=3 biological replicates, Day 3 post-transduction: → 73.9% iPSCs (vs. 23.7% LentiBOOST, 16.8% Polybrene) → 63.0% primary CD3⁺ T cells (vs. 15.3% LentiBOOST, 8.0% Polybrene) → 33.3% NK cells (vs. 6.0% Polybrene, 0.7% LentiBOOST)

Low MOI capability: >60% efficiency at MOI 1–2, enabling 5–10× lower MOI than competitor protocols.

Safety & quality: >90% cell viability, VCN of 2.8 ± 0.1 (below the FDA safety threshold), and a self-inactivating mechanism that eliminates lingering membrane disruption.

Simplified workflow: no spinoculation, no plate coating, <8 hours start to finish, compatible with closed-system GMP manufacturing.

Cost impact: 5–10× reduction in viral vector usage, potentially saving $25K–$250K per manufacturing batch.

Speaker
Dr. Archis Bagati, Ph.D. — Founder & CEO of PyrOjas Corporation and the inventor of HiTE™ Technology. Archis will present the science, walk through the head-to-head comparison data, and take your questions live via Zoom.

Who should attend:
Cell & gene therapy scientists - Process development engineers - CAR-T, CAR-NK, and iPSC researchers - CDMO and GMP manufacturing teams - Anyone working with lentiviral transduction 🍽

Lunch and coffee are provided.

Please RSVP with any dietary restrictions or allergies so we can accommodate. Learn more at www.hitebio.com

ZOOM: https://us06web.zoom.us/j/88279398067?pwd=Jf8ru2yF0HbaSxD0F5ot8Erzdpfugn.1